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Background: Since patients diagnosed with BRAF V600E and V600K mutated advanced melanoma show response
to treatment with MAP kinase inhibitors, several sensitive methods have been developed to determine the V600
allele status of melanoma patients. Vemurafenib (Zelboraf) and dabrafenib (Tafinlar) are specific BRAF V600
inhibitors recently approved by the US FDA as single agent treatments for unresectable or metastatic melanoma in
patients with the BRAF V600 mutation.
Methods: We assessed the new CE THxID™-BRAF diagnostic test, which is also FDA-approved as a companion
diagnostic test in the US under a specific reference and compared the results of this assay with both High
Resolution Melting (HRM) and Sanger sequencing in 113 melanoma FFPE samples.
Results: Invalid results were observed in 0/113 specimen with HRM, 5/113 (4.4%) with Sanger sequencing, and
1/113 (0.9%) with the THxID™-BRAF test. Positive percentage agreement (PPA) was 93.5% (95% CI 82.5 - 97.8) for
V600E and V600K mutations combined for the THxID™-BRAF test and HRM, and negative percentage agreement
(NPA) was 100.0% (95% CI 94.5 - 100.0). For the THxID™-BRAF test and Sanger, PPA was 100.0% (95% CI 92.1 - 100.0)
and NPA 100.0% (95% CI 94.2 - 100.0). One V600E sample identified by THxID™-BRAF test was detected as wild-type by
HRM and uninterpretable by Sanger. All V600K (n = 3) were detected using the 3 different approaches. Finally, percent
agreement values were not significantly different when using punches (n = 77) vs. slides (n = 36) or depending on
samples characteristics such as pigmentation, necrosis, and tumor content.
Conclusions: This study demonstrated the high agreement between the FDA approved THxID™-BRAF assay, HRM, and
Sanger sequencing. It has also highlighted the potential of THxID™-BRAF to be applied to a broader range of sample
types than claimed in the current “instructions for use”, an extension that would require the ad hoc validation
and approval.
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Melanoma is a cutaneous malignant tumor developed
from melanocytes. Melanoma is expected to be diagnosed
in 76,690 persons in the United States, and 9,480 patients
will die of the disease in 2013 [1]. As long as the disease
stays localized, cutaneous melanoma presents a favourable
prognosis. Indeed, the therapeutic coverage of the early-
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cure rate that approaches 90% [2]. However, a substantial
minority will develop disseminated disease (stage IV). The
prognosis for patients with stage IV melanoma has histor-
ically been poor, with median survival less than 1 year and
a 5-year overall survival rate of <10% [3].
The RAS/RAF/MEK/ERK pathway is a critical prolifera-
tion pathway in many human cancers. This pathway can
be constitutively activated by alterations in specific pro-
teins, including BRAF, which phosphorylates MEK on 2
regulatory serine residues. Over 45 cancer-associatedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have been identified at a high frequency in specific
cancers, including approximately 50 to 60% of melan-
oma. Approximately 90% of all identified BRAF muta-
tions that occur in human cancer are a T1799A
transversion mutation in exon 15, which results in a
V600E amino acid substitution [4] T1799A alteration
(V600E mutation) accounts for 70 to 90% of BRAF mu-
tant melanoma patients [5]. In addition, the T1799A
alteration can rather be associated with a second nu-
cleotide mutation (G1798A) and leads to a V600K mu-
tation in an additional ~6% to 29% of patients with a
BRAF mutation [6]. This mutation also provokes a
constitutional activation of the kinase protein.
Given that vemurafenib (PLX4032/RG7204) has been
recently approved by the Food and Drug Administration
(FDA) and the European Medicines Agency for treatment
of advanced metastatic melanoma as an inhibitor of V600
mutants, the need of a reliable test detecting the V600E
and V600K mutations for treatment with this drug has
risen. Until recently, the Cobas 4800 BRAF V600 Muta-
tion Test (Roche Molecular Diagnostics) was the only
FDA-approved assay for this purpose. However, this oligo-
nucleotide probe-based test primary detects V600E but in-
consistently V600K mutations – this allele is not claimed
in the intended use - that have been reported to account
for 6% to 30% of V600 mutations [6-9]. Since patients with
V600K have been shown to respond favourably to vemura-
fenib [4], alternative approaches for detecting mutations
V600K could help identify additional patients who could
benefit from BRAF inhibitor therapy.
Very recently (May 2013), a novel molecular test
THxID™-BRAF received FDA approval for com-
mercialization. In the US, this test is intended for select-
ing melanoma patients whose tumors carry the BRAF
V600E mutation for possible treatment with GlaxoS-
mithKline’s (GSK) Tafinlar (dabrafenib) as well as for
selecting melanoma patients whose tumors carry the
BRAF V600E or V600K mutation for possible treatment
with Mekinist (trametinib) [10]. Thus, the THxID™-
BRAF kit is an In Vitro Diagnostic device intended for
the qualitative and simultaneous detection of both
BRAF V600E and V600K mutations in DNA samples ex-
tracted from formalin-fixed paraffin-embedded (FFPE)
specimens. This test uses an ARMS* real-time PCR tech-
nology and must be performed on the ABI 7500 Fast Dx
platform [11].
In this study, we reported the first study assessing the
performance of the THxID™-BRAF kit in a clinical labora-
tory setting. 113 FFPE samples from patients with meta-
static melanoma were tested in parallel for BRAF V600
mutation detection using THxID™-BRAF kit and two
other well-established methods: bidirectional Sanger se-
quencing and High Resolution Melting (HRM).Methods
Tissue samples
Melanoma tissue samples (n = 113) were retrospectively
obtained between 2010 and 2013 and were handled by the
Department of Pathology (Montpellier, France). The insti-
tutional university hospital (Montpellier, France) review
board approved all of the protocols. Tissues were proc-
essed for formalin fixation and paraffin-embedding using a
TissueTek VIP automated processor (Bayer HealthCare
Diagnosis Division). FFPE samples were sectioned using a
microtome to obtain 5 μm thick slides, while FFPE punch
samples (0.6 cm diameter carrots) were obtained from in-
dependent specimens. In order to estimate the tumor con-
tent for each sample, hematoxylin eosine staining (HE)
were realized and analyzed by two pathologists. The ne-
crosis content and the melanin rate were evaluated from
the HE slides.
DNA extraction
Tumor DNA was extracted from paraffin-embedded tissue
samples using THxID™- BRAF PUR kit according to the
manufacturer’s recommendations. With this protocol,
most fixed, paraffin embedded tissue samples yielded
DNA of good quality as measured by Nanodrop.High resolution melting
BRAF exon 15 was PCR-amplified using a LightCycler
480 HRM Master Reaction Mix (Roche Diagnostics).
Each 10 μL reaction volume was comprised of 20 ng
genomic DNA, 8 μl reaction mix, 3.0 mM MgCl2 and
0.3 mM each of the forward and reverse primers. The
primer sequences are as follow: BRAF-F: 5′- TCAT-
GAAGACCTCACAGTAAAAATAGG -3′, and BRAF-R:
5′- AGCAGCATCTCAGGGCCAAA -3′. The cycling
conditions were identical for all amplifications and were as
follows: 95°C for 10 min, followed by 50 cycles of 95°C for
15 s, 63°C for 15 s with an initial 11 cycles of touchdown
(0.5°C/cycle), and 72°C for 25 s. The melting conditions
included one cycle of 95°C for 1 min, one cycle of 40°C
for 1 min and one cycle of 70°C for 5 s, followed by a
gradual increase from 75°C to 95°C at 0.1°C per sec-
ond. The HRM data were analyzed using the LightCy-
cler 480 software release 1.5.0 SP4. For each sample, the
normalized melting curves were evaluated, and the sam-
ples were compared with the wild-type sample controls
and a mutant sample control in a deduced difference
plot. Significant deviations from the horizontal line rela-
tive to the spread of the wild-type controls were indica-
tive of sequence changes within the analyzed amplicon.
The samples with distinct melting curves compared
with the wild-type allele and the mutant allele were re-
corded as positive mutations. All samples were tested
in duplicate.
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A Mix solution was prepared with Buffer (Thermo-Start
PCR Buffer 10X, Thermo Scientific), MgCl2 (Magnesium
Chloride Sol. 25 mM, Thermo Scientific), 50 mM dNTPs
(Thermo Scientific) and Taq Polymerase (Platinum Taq
DNA Polymerase 5U/μl, Invitrogen). To this solution, a
primer pair at 10 mM corresponding to the targeted exon
15 of BRAF gene was added (amplicon 112 pb). These
primers are the following ones: forward 5′- TGTAAA
ACGACGGCCAGTCCTCAGATATATTTCTTCATG-3′
and reverse 5′- CAGGAAACAGCTATGACCGATCC
AGACAACTGTTCAA-3′. CO-amplification at Lower
Denaturation temperature-PCR (COLD-PCR) was per-
formed in 50 μl reaction containing 50 ng of each
DNA samples are added to this solution and amplified
using the GeneAmp PCR System 2700 (ABI) at the fol-
lowing program: 95°C for 11 min, 14 cycles of 95°C for
40 sec then 55°C for 40 sec then 72°C for 50 sec, 21 cy-
cles changing 95°C for 40 sec then 60°C for 40 sec then
72°C for 50 sec and 72°C for 5 min. The product ob-
tained is filtered through a LSKM PCR50 Multiscreen
Filter Plate (Millipore) and dispatched in two samples
in order to be marked with the Big Dye Terminator
v1.1 cycle Sequencing RR-100 (Life Technologies),
(one with a Forward genomic primer and one with a
Reverse genomic primer) using the universal m13
primers. Still using the GeneAmp PCR System 2700
(ABI), the following program is run: 96°C for 2 min
and 25 cycles of 96°C for 30 sec then 50°C for 15 sec
then 60°C for 4 min. After that, this marked product is
filtered using the Sephadex G-50 Superfine powder
(GE HealthCare) in an AcroPrep 96-well Filter Plate
(Pall) and transferred in a 96-well PCR plate AB-1400
(Thermo Scientific) which is inserted into the mount-
ing system intended to be used with the 3130xl Gen-
etic Analyzer (ABI Prism). The electrophoregrams
supplied by this platform are then studied to determine
whether the 600th codon of the 15th exon of BRAF is
mutated or not.
THxIDTM-BRAF assay
For the slide samples, a macrodissection was realized to
maximize the tumor content and the chosen tissue area
was removed from the slide with a sterile scalpel and
put down into a sterile microtube. The punch samples
were directly put into the sterile microtube. Whether
the samples are prepared from slide or from punch, the
extraction was always carried out the same way with
the THxID™-BRAF PUR DNA Extraction Kit following
the manufacturer’s protocol. The THxID™-BRAF kit, the
DNA does not need to be quantified; the slide samples
must present a surface from 40 to 500 mm2. Of note,
the manufacturer does not describe the use of punch
samples in the instructions for use.Following the manufacturer's protocol spheres of
V600E and V600K primers are suspended in the buffer
and blended with the Mix containing all the other re-
agents needed for the PCR reaction (dNTP, Taq Poly-
merase, MgCl2, etc.). Two μl of each DNA sample are
added to this Master Mix solution and amplified using
the 7500 Fast Dx platform (Applied Biosystems). The
principle of the THxIDTM-BRAF assay kit is based on
an ARMS-PCR approach [11]. In the PCR reaction,
primers specific for the BRAF gene allow the amplifica-
tion of a non-polymorphic gene area, which is used as
an internal control. The primers specific for the muta-
tions V600E and V600K allow the amplification of mu-
tated fragments leading to the identification of BRAF
mutations whereas HRM can only detect changes in the
melting profile requiring additional Sanger sequencing
to precisely identify the BRAF mutation. In THxID™-
BRAF kit, 2 different probes labeled with 2 different
dyes allow the simultaneous detection of the BRAF in-
ternal control and a BRAF mutation. Kinetic analysis of
the fluorescent signals and delta Ct (Crossing threshold)
calculation reveal the presence of potential BRAF muta-
tions. The qualitative results (wild-type, mutated V600E
and/or V600K, invalid) are supplied as a report. THxIDTM-
BRAF kit technical validation has been performed previ-
ously by bioMerieux US and is reported in manufacture’s
recommendations.
Validation or invalidation test definitions
The THxID™-BRAF software interprets the results auto-
matically and highlights the presence of valid or invalid re-
sults in the generated report. The 2 possible outcomes for
Positive and Negative Controls are “valid” or “invalid”. If
one or more controls are invalid, the results of the clinical
specimen obtained in the run are not reported. In such
case, the complete run must be repeated using frozen
sample eluates, frozen Negative Control eluate and either
frozen Positive Control if available or a new preparation.
The result validity of clinical specimens is determined by
the internal control Ct values that should fall within pre-
specified limits, following the manufacture’s recommenda-
tions. A result is considered as invalid if one of the delta
Ct or internal control Ct values falls outside the expected
limits. In our study, Sanger sequencing and HRM test re-
sults were considered as invalid when DNA could not be
amplified. The failure of fragment amplification could
probably be due to the high degradation of FFPE-used ma-
terial, as largely reported previously [12].
Statistical analysis
For method correlation, the two-sided 95% confidence in-
tervals were calculated using the Wilson method [13].
Evaluation of percent agreements was calculated for
THxID™ BRAF against HRM as a reference on the one














Others (intestine, bone, etc.) 6 8.3
Average age (years) 63.2
Sample type
Slide 36 31.9
Tissue surface mean (mm2) 97.2
[DNA] (ng/μl) 38.7
Punch 77 68.1






Sample 0 105 92.9
Sample + (5 to 15%) 5 4.4
Sample ++ (20 to 45%) 2 1.8
Sample +++ (>50%) 1 0.9
Necrosis rate
Sample 0 92 81.4
Sample + (<10%) 15 13.3
Sample ++ to +++ (>10%) 6 5.3
1After macro-dissection, when applicable.
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comparing two methods, overall percent agreement was
calculated from the number of specimens tested positive
and negative by both methods, and the total number of
specimens. Positive percent agreement was calculated
from the number of specimens tested positive by both
methods, and the total numbers of specimens tested posi-
tive for the method of reference (HRM or Sanger). Nega-
tive percent agreement was calculated from the number of
specimens tested negative by both methods, and the total
numbers of specimens tested negative for the method
of reference. Fisher‘s exact test was used to compare
methods and pathological characteristics. Differences were
considered statistically significant when p-values < 0.05.
Results
Melanoma tissue cohort
113 samples were included in the method comparison
analysis. 36 corresponded to slide samples and 77 to
punch samples. The average surface and the average
DNA concentration of the slides were 97.2 mm2 and
38.7 ng/μl, respectively. The average depth and the aver-
age DNA concentration of the punches reach 1.02 mm3
and 266 ng/μl, respectively. Among the 36 slide samples,
13 showed a tumor percentage lower than 80%, 5 con-
tained a melanin rate higher than 0 and 10 had necrotic
tissue (from “ + ” = very low to “+++” = high). Among the
77 punch samples, none showed a tumor percentage
lower than 80%, 3 had high melanin rate, and 11 had
necrotic tissue (from “ + ” = very low to “++” = low).
Sample characteristics are shown in Table 1.
Invalid test rate
Following initial testing and retesting (when necessary),
final invalid rates of 0/113 (0%), 5/113 (4.4%), and 1/113
(0.9%) were obtained for the HRM, Sanger sequencing,
and THxID-BRAF kit, respectively (Table 2). The single
invalid sample obtained with THxID™-BRAF was found
positive for V600E using HRM and Sanger sequencing.
Of the 5 samples with invalid Sanger sequencing results,
4 were wild-type (WT) with HRM and THxID™-BRAF
whereas one was negative for HRM but positive for
V600E for THxID™-BRAF. These invalided samples were
excluded depending on each pair of comparisons for
further analysis.
Method correlation between the THxID™-BRAF Test and
HRM and sanger sequencing
Among the specimens, 44 of 113 (38.9%), and 46 of 108
(42.6%) samples were positive for V600 mutation by
HRM, and Sanger sequencing, respectively. THxID™-
BRAF method detected a V600 mutation in 46 of 112
(41.1%) samples as well. Same status among all 3 assays
was observed in 105 of 107 samples (98.1%). Consensusbetween HRM and Sanger sequencing, and THxID™-
BRAF test and Sanger sequencing were observed in 106
of 108 samples (98.1%) and 107 of 107 samples (100%),
respectively. Consensus between HRM and THxID™-
BRAF test was observed in 109 of 112 samples (97.3%).
For method correlations, overall, positive, and negative
agreements between the THxID™-BRAF test and the two
other methods (HRM and Sanger sequencing) were also
assessed (Table 3). Three of 46 samples with a V600 mu-
tation detected by Sanger sequencing had a V600K
(c.1798_1799GT > AA) mutation. Regarding the HRM
Table 2 Invalid test rates
Assay Invalid test Invalid rate (%)
HRM (n = 113) 0 0
Sequencing (n = 113) 5 4.4
7500 Fast Dx (n = 113) 1 0.9
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vealed a characteristic shape, different for V600E or
non-mutated samples, thus allowing the detection of
BRAF V600K mutation (Figure 1). This latter mutation
was systematically detected with the bidirectional Sanger
sequencing and the THxID™-BRAF assay (Figure 1).
Impact of pathological characteristics on analytical
performance
The impact of pathological characteristics (melanin con-
tent, necrosis, and tumor content) was first assessed on
the valid samples used for the agreement analysis
(Table 4). No significant effect on V600 mutation detec-
tion or WT detection by HRM, Sanger sequencing, and
THxID™-BRAF test was observed. We then tested the ef-
fect of these pathological characteristics on the invalid
rate. Among the 5 invalid samples on Sanger sequen-
cing, one showed high melanin content and 2 had a
tumor content < 80% after macro-dissection. The only
invalid sample on THxID™-BRAF presented a low rate of
necrosis. Thus, no correlation was found between these
parameters and invalid results. Finally, we determined
whether sample format (section vs. punch) could impact
BRAF genotyping: results showed no significant differ-
ence depending on tissue pre-analytical procedure.
Discussion
It is now well established that the frequency of detected
BRAF V600E mutations in cutaneous melanoma is influ-
enced by the analytical sensitivity of the method applied
for their detection [14]. Multiple methods have been de-
veloped to detect BRAF mutations, including competitive
allele-specific Taqman [15], amplification refractory muta-
tion system-PCR [16], HRM [17], bidirectional Sanger se-
quencing, and pyrosequencing [18]. Several studies haveTable 3 Method correlations between THxID™-BRAF test and
HRM
M WT
THxID™-BRAF test M 43 0
WT 3 66
Total 46 66
Positive agreement 93.5 (95% CI 82.5 - 97.8)
Negative agreement 100.0 (95% CI 94.5 - 100.0)
Overall agreement 97.3 (95% CI 92.4 - 99.1)
M: Mutation; WT: Wild-type.proposed to compare several PCR-based methods demon-
strating differences in the sensitivity, specificity, costs,
hands-on-time, and feasibility [19-23]. Until recently, the
only FDA-approved BRAF c.1799 T > A mutation detec-
tion test was the Cobas 4800 BRAF V600 Mutation Test.
However, this test seems to lack analytical sensitivity to
detect mutations in small tumors. Several findings sug-
gested that this test might occasionally falsely classify
other BRAF mutations, missing V600K, and therefore
patients who might benefit from therapy with BRAF
inhibitors [24-28].
Recently, bioMérieux has developed and marketed a
new THxID™-BRAF FDA-approved companion diagnostic
test, related to the dabrafenib and trametinib drug devel-
opment by GSK. However, this test has never been investi-
gated to date [10]. THxID™-BRAF used an ARMS based
PCR technology. ARMS PCR approaches have been widely
and successfully used to detect somatic mutation in rou-
tine research, notably BRAF mutations [16,29,30]. One of
the advantages of ARMS-PCR is that the assay is designed
to amplify a relative larger common fragment of DNA that
flanks the mutation site in all samples regardless of their
mutation status. In our PCR reaction, primers specific
for the BRAF gene allow the amplification of a non-
polymorphic gene area, which was used as an internal
control to check for template DNA quality as well as po-
tential PCR inhibition. The mutant or wild-type specific
PCR amplifications take place in the same reaction tube,
thereby allowing the mutant or wild-type specific PCR
primers to compete for binding to very limited templates.
Here, we reported a high consensus between both HRM
and Sanger sequencing and THxID™-BRAF to detect
V600E and V600K mutations in melanoma samples. Inter-
estingly, two samples were detected as WT in the HRM
technique while the Sanger sequencing and the THxID™-
BRAF test found aV600E mutation. Moreover, one sample
recorded as invalid because of the non-amplification by
the Sanger sequencing was detected as WT by the HRM
and V600E by the THxID™-BRAF test. The overall fre-
quency of V600 mutation in our study was 38.9% by
HRM, 42.6% by Sanger sequencing, and 41.1% by
THxID™-BRAF. This rate is concordant with severalHRM and Sanger sequencing
Sanger sequencing
Total M WT Total
43 45 0 45
69 0 62 62
112 45 62 107
100.0 (95% CI 92.1 - 100.0)
100.0 (95% CI 94.2 - 100.0)
100.0 (95% CI 96.5 - 100.0)
Figure 1 Representative results for BRAF V600 mutation detection. Detection of V600E (A) and V600K (B) mutation using HRM. Normalized
high-resolution melting curves (upper panel). The differences plot displays the melting curve of each tested sample subtracted from the reference curve
obtained by analyzing a control wild-type BRAF sequence (below panel). Detection of V600E (C) and V600K (D) mutation using Sanger sequencing.
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MEK inhibitors [32] with approximately 35% to 60%
[4,31-33]. All of the 3 V600K mutations identified by
Sanger sequencing were detected by the THxID™-BRAF
assay, and HRM missed one V600E mutation. Finally,
when considering all V600 variants, no statistical differ-
ences in detection rates between the 3 methods could
be observed.
Several histological parameters have been assessed. Thus,
the lowest tumor content with a mutation detected in our
study was 75% (after macro-dissection). It is possible that
the test could detect mutation in smaller subpopulation of
tumor cells carrying the mutation. However, it is important
to take into account that this cut-off is difficult to estimate
since several studies showed difficulties to standardize this
parameter. Among the 8 samples with elevated melanin
content, only one relatively low melanin sample couldn’t
be amplified using Sanger sequencing. The only discordant
sample between HRM and THxID™-BRAF shows a verylow content of necrosis. However, many samples have a
higher content of necrosis without being invalid. In
addition, among the 13 samples that present a tumor con-
tent < 80%, 2 were invalid on Sanger sequencing and one
of them non concordant between HRM and THxID™-
BRAF. Besides, this sample was one of the samples with
the lowest percentage of tumor cells. Finally, no statistical
difference was found between slide and punch prepar-
ation. Altogether, these results demonstrated the absence
of correlation between histological parameters and BRAF
status determination.
Currently, only metastatic melanoma patients carrying
the V600E mutation have been evaluated for response to
vemurafenib in clinical trials [34]. However, it is likely that
tumors with other less common BRAF mutation such as
c.1798_1799GT > AA (V600K) mutation, c.1798_179
9GT > AG (V600R) mutation, c.1799_1800TG > AA
(V600E rare variant) mutation, and several other codon
600 mutations could also respond to treatment with
Table 4 Pathological characteristics and analytical performances of each method
WT V600 mutation Invalid result













Samples <80% 12 10 11 1 1 2 0 2 0
Samples ≥80% 57 52 55 41 45 44 0 3 1
Melanin rate
Sample 0 62 56 59 40 45 45 0 4 1
Sample + (>20%) 4 3 4 1 1 1 0 1 0
Sample ++ (20 to 50%) 2 2 2 0 0 0 0 0 0
Sample +++ (≤50%) 1 1 1 0 0 0 0 0 0
Tumor necrosis
Sample 0 55 49 53 34 38 39 0 5 0
Sample + (<10%) 10 9 9 5 6 5 0 0 1
Sample ++ to +++ (≥10%) 4 4 4 2 2 2 0 0 0
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important implications for determining eligibility for
treatment with BRAF or MEK inhibitors. In preclinical
studies, vemurafenib was reported to strongly inhibit
melanoma cell lines expressing V600K (or other V600
variants), in addition to those expressing V600E [35]. In
addition, in the phase III clinical trial of vemurafenib
versus dacarbazine, 10 patients in the vemurafenib
group did not carry the BRAF c.1799 T > A (V600E)
mutation (despite testing positive by the Cobas test) [4].
Retrospective Sanger and 454 sequencing instead revealed
a V600K mutation, and four of these 10 patients had a par-
tial response. Moreover, in Sosman et al. phase II trial re-
port, 132 patients had BRAF V600-positive mutation (122,
with the V600E mutation and 10 with the V600K muta-
tion). Among the 10 patients with BRAF V600K muta-
tions, 4 (40%) had a partial response, 3 (30%) had stable
disease, 2 had progressive disease (20%), and 1 could not
be assessed [31]. Similar results were reported from a trial
of trametinib, a selective inhibitor of MEK1 and MEK2
proteins. MEK1 and MEK2 are normally phosphorylated
by BRAF and go on to activate downstream components
of the mitogen-activated protein kinase pathway. There-
fore, inhibition of these proteins also blocks the effects of
BRAF activation. Finally, in the trametinib trial, patients
with V600K showed improvements in progression and
overall survival rates similar to those of patients with
V600E [32].
Dabrafenib is a specific BRAF V600 inhibitor (BRAFi)
approved by the US FDA as a single agent treatment for
unresectable or metastatic melanoma in patients with the
BRAF V600E mutation as detected by an FDA-approved
test [36]. Dabrafenib is also FDA-approved as a combin-
ation therapy with trametinib for the treatment of patients
with unresectable or metastatic melanoma with a BRAFV600E/K mutation. However, this drug is also proposed in
phase II for brain metastases (from melanoma), and other
solid tumours, such as colorectal cancer and non-small
cell lung cancer. Therefore, it would be interesting to have
on the market an IVD BRAF test such as the THxID™-
BRAF assay to detect V600 mutation in colorectal cancer
and non-small cell lung cancer.
Conclusions
When applying a particular method for routine diagnostic
testing, it must achieve a sufficient sensitivity without com-
promising accuracy while being convenient and cost-
efficient. In our study, the THxID™-BRAF assay obtained
results comparable to the reference methods. However, the
main issue to propose its use as a first screening test for
BRAF genotyping in routine laboratories probably remains
its cost. Sanger sequencing has a better cost-per-assay rele-
vance. However, it has also relatively low analytical sensitiv-
ity, meaning that a mutation must be present in >15% to
20% of tumor cells to be detected. Lower prevalence of
BRAF mutation was reported in studies that used sequen-
cing as the sole method of mutation analysis [6]. Thus, sole
reliance on the Sanger sequencing assay could miss identi-
fication of many patients who might benefit from therapy
with BRAF inhibitors. Finally, although HRM as a relative
high sensitivity for mutation detection, it failed to detect 3
(2.6%) samples with V600 mutation. Therefore, in accord-
ance to our results, we believe that THxID™-BRAF assay
could be used as a second-line test for samples that are
negative on Sanger sequencing and HRM as well as in case
of discordant results between these two methods. This ra-
tional approach could maximize the potential benefit of
BRAF V600 or MEK inhibitors, even though the accuracy
of the THxID™-BRAF assay is fully relevant for a first line
use. In addition, THxID™-BRAF is a simple and fast
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than a thermocycler. The estimated duration time for this
protocol is less than 24 hours (from the reception of the
sample to the delivery of the final report to clinician). Since
the response time for tests of BRAF status is a major issue,
this procedure could also offer new opportunities to signifi-
cantly enhance sample throughput, decrease turnaround
time, and propose an interesting alternative solution in
“urgent” cases.
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